Please select the option that best describes you:
Are certain PD-L1 assays considered more accurate or reliable than others for NSCLC?
How do the different assays compare when choosing a specific immunotherapy, and does this change for first vs second (or beyond) line of therapy?
Answer from: Medical Oncologist at Academic Institution
In the treatment of NSCLC, squamous or non-squamous, there are three potential checkpoint antibodies available (Nivolumab, Pembrolizumab and Atezolizumab), only one of which is tied to a companion diagnostic of PDL1 expression by IHC (Pembrolizumab) - though in both of the other antibodies, there is...
Sign in or Register to read more